What’s the current market cap for Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals (ALNY) has a market cap of $39bn as of June 27, 2026.

What is the P/E ratio for Alnylam Pharmaceuticals stock?

The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 73.76 as of June 27, 2026.

Does Alnylam Pharmaceuticals stock pay dividends?

No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of June 27, 2026.

When is the next Alnylam Pharmaceuticals dividend payment date?

Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.

What is the beta indicator for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Alnylam Pharmaceuticals stock | $ALNY Share Price

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Ticker

$ALNY

Sector

Health

Primary listing

NASDAQ

Employees

2,500

Headquarters

Cambridge, United States

Website

www.alnylam.com

ALNY Metrics

BasicAdvanced

$39bn

73.76

$3.95

0.30

-

What the Analysts think about ALNY

Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.

Bulls say / Bears say

Achieved a landmark first-quarter 2026 net product revenue of $1.036 billion (up 121% YoY), driven by total TTR revenues of $910 million (153% YoY), marking the first time product revenues surpassed $1 billion in a quarter and demonstrating strong commercial execution (Nasdaq).

Reiterated full-year 2026 net product revenue guidance of $4.9–$5.3 billion, representing ~71% growth at the midpoint year-over-year, highlighting management’s confidence in sustained franchise momentum (SEC Form 8-K).

Established collaborations with Viz.ai and the American Heart Association focused on earlier ATTR-CM diagnosis and coordinated care, expected to broaden patient reach and reinforce AMVUTTRA uptake over the long term (Nasdaq).

Guided non-GAAP R&D and SG&A expenses of $2.7–$2.8 billion for 2026, significantly higher than the prior year, which may strain free cash flow if revenue growth does not keep pace (SEC Form 8-K).

Product gross margin on Q1 2026 product sales compressed to 80% from 85% in Q1 2025, primarily due to escalating royalty rates on Amvuttra, signaling mounting cost headwinds as volumes ramp (Alnylam Q1 2026 Presentation).

The TTR portfolio accounted for roughly 88% of Q1 2026 net product revenues ($910 million of $1.036 billion), concentrating revenue exposure in a single franchise and heightening vulnerability to competitive or reimbursement shifts in the ATTR market (Nasdaq).

Data summarised monthly by Lightyear AI. Last updated on 20 Jun 2026.

ALNY Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ALNY Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ALNY News

AllArticlesVideos

The Healthcare M&A Wave

Forbes·1 week ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Business Wire·2 weeks ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Business Wire·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.